Emami Ltd
Emami is engaged in manufacturing & marketing of personal care & healthcare products with an enviable portfolio of household brand names such as BoroPlus, Navratna, Fair and Handsome, Zandu Balm, Kesh King, Zandu Pancharishta, Mentho Plus Balm and others.(Source : 201903 Annual Report Page No: 193)
- Market Cap ₹ 27,973 Cr.
- Current Price ₹ 641
- High / Low ₹ 860 / 417
- Stock P/E 35.1
- Book Value ₹ 63.5
- Dividend Yield 1.23 %
- ROCE 31.3 %
- ROE 29.3 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 32.0%
- Company has been maintaining a healthy dividend payout of 51.1%
Cons
- Stock is trading at 10.1 times its book value
- The company has delivered a poor sales growth of 3.26% over past five years.
- Tax rate seems low
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: FMCG Industry: Personal Care - Indian
Part of BSE 500 Nifty Midcap 150 Nifty LargeMidcap 250 BSE Quality Index Nifty 500 Multicap 50:25:25
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1,531 | 1,595 | 1,904 | 2,150 | 2,302 | 2,354 | 2,489 | 2,390 | 2,582 | 2,867 | 2,907 | 2,922 | 2,987 | |
1,182 | 1,167 | 1,393 | 1,495 | 1,562 | 1,654 | 1,782 | 1,798 | 1,738 | 1,970 | 2,129 | 2,070 | 2,098 | |
Operating Profit | 348 | 428 | 511 | 655 | 739 | 700 | 706 | 592 | 845 | 897 | 777 | 852 | 889 |
OPM % | 23% | 27% | 27% | 30% | 32% | 30% | 28% | 25% | 33% | 31% | 27% | 29% | 30% |
56 | 61 | 103 | 38 | 45 | 28 | 27 | 91 | 103 | 123 | 48 | 63 | 127 | |
Interest | 6 | 4 | 5 | 54 | 58 | 33 | 19 | 19 | 12 | 3 | 4 | 2 | 2 |
Depreciation | 21 | 33 | 31 | 252 | 305 | 305 | 318 | 326 | 361 | 328 | 215 | 167 | 163 |
Profit before tax | 377 | 452 | 577 | 387 | 422 | 389 | 396 | 338 | 574 | 689 | 606 | 747 | 851 |
Tax % | 14% | 12% | 18% | 14% | 18% | 20% | 23% | 14% | 17% | -23% | 5% | 7% | |
324 | 398 | 472 | 332 | 346 | 310 | 305 | 289 | 475 | 851 | 574 | 693 | 791 | |
EPS in Rs | 7.13 | 8.77 | 10.39 | 7.32 | 7.63 | 6.82 | 6.72 | 6.37 | 10.69 | 19.28 | 13.00 | 15.89 | 18.12 |
Dividend Payout % | 37% | 40% | 34% | 48% | 46% | 51% | 59% | 63% | 75% | 41% | 62% | 50% |
Compounded Sales Growth | |
---|---|
10 Years: | 6% |
5 Years: | 3% |
3 Years: | 4% |
TTM: | 2% |
Compounded Profit Growth | |
---|---|
10 Years: | 5% |
5 Years: | 17% |
3 Years: | 15% |
TTM: | 27% |
Stock Price CAGR | |
---|---|
10 Years: | 5% |
5 Years: | 15% |
3 Years: | 5% |
1 Year: | 26% |
Return on Equity | |
---|---|
10 Years: | 26% |
5 Years: | 27% |
3 Years: | 32% |
Last Year: | 29% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 15 | 23 | 23 | 23 | 23 | 23 | 45 | 45 | 44 | 44 | 44 | 44 | 44 |
Reserves | 762 | 906 | 1,189 | 1,537 | 1,690 | 1,949 | 2,019 | 1,757 | 1,715 | 2,042 | 2,220 | 2,339 | 2,730 |
72 | 31 | 24 | 660 | 435 | 279 | 54 | 158 | 51 | 224 | 21 | 22 | 23 | |
302 | 300 | 320 | 312 | 294 | 347 | 464 | 475 | 493 | 516 | 467 | 441 | 598 | |
Total Liabilities | 1,152 | 1,260 | 1,556 | 2,532 | 2,441 | 2,598 | 2,583 | 2,435 | 2,304 | 2,826 | 2,751 | 2,847 | 3,394 |
374 | 374 | 424 | 1,894 | 1,952 | 1,763 | 1,643 | 1,422 | 1,100 | 1,270 | 1,088 | 960 | 894 | |
CWIP | 44 | 8 | 25 | 60 | 20 | 30 | 36 | 8 | 6 | 3 | 2 | 5 | 7 |
Investments | 164 | 296 | 502 | 95 | 128 | 315 | 187 | 161 | 264 | 361 | 392 | 560 | 939 |
570 | 582 | 605 | 482 | 340 | 489 | 716 | 844 | 934 | 1,192 | 1,270 | 1,322 | 1,556 | |
Total Assets | 1,152 | 1,260 | 1,556 | 2,532 | 2,441 | 2,598 | 2,583 | 2,435 | 2,304 | 2,826 | 2,751 | 2,847 | 3,394 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
327 | 378 | 497 | 534 | 715 | 577 | 513 | 546 | 878 | 596 | 731 | 740 | |
-119 | -130 | -217 | -1,294 | -261 | -237 | 20 | -251 | -200 | -188 | -106 | -192 | |
-202 | -264 | -221 | 511 | -519 | -331 | -434 | -399 | -679 | -398 | -612 | -546 | |
Net Cash Flow | 6 | -15 | 59 | -249 | -64 | 9 | 99 | -105 | -0 | 10 | 13 | 1 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 19 | 17 | 11 | 9 | 5 | 11 | 21 | 28 | 14 | 25 | 33 | 35 |
Inventory Days | 59 | 76 | 58 | 68 | 81 | 86 | 89 | 102 | 116 | 123 | 102 | 102 |
Days Payable | 43 | 64 | 62 | 89 | 72 | 86 | 94 | 108 | 120 | 111 | 85 | 91 |
Cash Conversion Cycle | 35 | 30 | 7 | -12 | 15 | 11 | 16 | 22 | 10 | 37 | 50 | 46 |
Working Capital Days | -10 | -1 | -9 | 5 | -39 | 18 | 20 | 36 | 10 | 35 | 44 | 44 |
ROCE % | 44% | 51% | 61% | 29% | 24% | 23% | 19% | 17% | 30% | 31% | 26% | 31% |
Documents
Announcements
-
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
30 Nov - Intimation of lost share certificate by shareholder.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
29 Nov - Company through its senior management will be participating in the IIFL Securities Ltd., Investor''s event to be held on Thursday, 5th December, 2024.
-
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
22 Nov - Intimation of lost share certificate by shareholder.
-
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
22 Nov - Disclosure under SEBI regulations for share encumbrance.
-
Announcement under Regulation 30 (LODR)-Updates on Acquisition
21 Nov - Acquired remaining 1.70% stake in Helios Lifestyles.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
Concalls
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Jun 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Feb 2024TranscriptNotesPPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
Aug 2023TranscriptNotesPPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Nov 2022TranscriptNotesPPT
-
Aug 2022Transcript PPT
-
Jun 2022TranscriptNotesPPT
-
May 2022TranscriptNotesPPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Jun 2021Transcript PPT
-
Feb 2021Transcript PPT
-
Feb 2021Transcript PPT
-
Nov 2020Transcript PPT
-
Aug 2020TranscriptNotesPPT
-
Aug 2020Transcript PPT
-
Jul 2020Transcript PPT
-
Feb 2020TranscriptPPT
-
Dec 2019TranscriptPPT
-
Nov 2019TranscriptPPT
-
Aug 2019Transcript PPT
-
May 2019TranscriptPPT
-
Jan 2019TranscriptPPT
-
Oct 2018Transcript PPT
-
Aug 2018Transcript PPT
-
Aug 2018TranscriptNotesPPT
-
May 2018TranscriptPPT
-
Jan 2018TranscriptNotesPPT
-
Nov 2017Transcript PPT
-
Feb 2017TranscriptPPT
-
Oct 2016TranscriptPPT
-
Aug 2016Transcript PPT
-
May 2016Transcript PPT
-
Jan 2016TranscriptPPT
Leadership in Niche segments:[1] Emami is one of the leading companies in the personal and healthcare segment with leadership in the niche Ayurvedic segment. The Company has a portfolio of 450+ products based on ayurvedic formulations.